Professor Mark Evans

Rajna Golubic, Jane Kennet, Victoria Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Phil Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark Evans Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15579. Epub ahead of print. PMID: 38562018. 

Rajna Golubic, Mouhamad Hussein Ismail, Masa Josipovic, Jane Kennet, Alfonso Galderisi, Mark L Evans. Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: a double-blinded placebo-controlled cross-over trial. Diabetes Obes Metab. 2023 Oct;25(10):3059-3063. doi: 10.1111/dom.15176. Epub 2023 Jun 13. PMID: 37312648 

Ali J Chakera, Paul S Hurst, Gill Spyer, Emmanuel Ogunnowo-Bada,William J Marsh, Christine H Riches, Chen-Yu Yueh, S Pauliina Markkula, Jeffrey W Dalley, Roger D Cox, Ian A Macdonald, Stephanie A Amiel, Kenneth M MacLeod, Lora K Heisler, Andrew T Hattersley, Mark L Evans. Molecular Reductions in Glucokinase Activity Increase Counter-regulatory Responses to Hypoglycemia in Mice and Humans with Diabetes. Molecular Metabolism 2018 Nov;17:17-27. PMID: 30146176 

Burke L, Ogunnowo-Bada E, Georgescu T, Cristiano C, Martinez de Morentin PB, Torres LV, D’Agostino G, Riches CR, Heeley N, Ruan Y, Rubinstein M, Low MJ,  Myers MG, Rochford JJ, Evans ML*, Heisler LK*. * = co-corresponding author. Lorcaserin improves glycemic control via a melanocortin neurocircuit. Molecular Metabolism 6(10):1092-1102 Oct 2017. PMID: 29031711 

Sankalpa Neupane, Robert Peverall, Graham Richmond, Tom P.J. Blaikie, David Taylor, Gus Hancock and Mark L. Evans. Exhaled Breath Isoprene Rises During Hypoglycemia in Type 1 Diabetes. Diabetes Care 2016 Jul; 39(7): e97-e98. PMID 27330135 

Other recent Publications: 

Divilly P, Martine-Edith G, Zaremba N, Søholm U, Mahmoudi Z, Cigler M, Ali N, Abbink EJ,  Brøsen J,  de Galan B, Pedersen-Bjergaard U, Vaag AA, McCrimmon RJ, Renard E, Heller S, Evans M, Mader JK, Amiel SA, Pouwer F, Choudhary P for the Hypo-RESOLVE Consortium. The relationship between sensor-detected hypoglycemia and patient-reported hypoglycemia in people with type 1 and insulin-treated type 2 diabetes: The Hypo-METRICS study. Accepted Diabetes Care July 2024 

Søholm U, Broadley M, Zaremba N, Divilly P, Baumann PM, Mahmoudi Z, Martine-Edith G, Mader JK, Cigler M, Brøsen JMB, Vaag A, Heller S, Pedersen-Bjergaard U, McCrimmon RJ, Renard E, Evans M, de Galan B, Abbink E, Amiel SA, Hendrieckx C, Speight J, Choudhary P, Pouwer F on behalf of the Hypo-RESOLVE consortium. The impact of hypoglycaemia on daily functioning among adults with diabetes: a prospective observational study using the Hypo-METRICS Application. Accepted Diabetologia April 2024  

Arshad MF, Walkinshaw E, Solomon AL, Bernjak A, Rombach I, Leelarathna L, Little SA, Evans M, Shaw JAM, Heller SR, Iqbal A. Diabetic autonomic neuropathy does not impede improvement in hypoglycaemia awareness in adults: Sub-study results from the HypoCOMPaSS trial. Diabet Med. 2024 Sep;41(9):e15340. doi: 10.1111/dme.15340 

Zaremba N, Martine-Edith G, Divilly P, Søholm U, Broadley M, de Galan B, Mader JK, Pedersen-Bjergaard U, Evans M, Renard E, McCrimmon RJ, Heller S, Speight J, Pouwer F, Amiel SA, Choudhary P for the Hypo-RESOLVE Consortium. Associations of clinical, psychological, and sociodemographic characteristics and ecological momentary assessment completion in the 10-week Hypo-METRICS study: Hypoglycaemia MEasurements ThResholds and ImpaCtS. Accepted Diab Med April 2024 

Svensson CH, Fabricius TW, Verhulst CEM, Kristensen PL, Tack CJ, Heller S, Amiel S, McCrimmon RJ, Evans M, Holst JJ, de Galan BE, Pedersen-Bjergaard U, on behalf of the Hypo-RESOLVE consortium. The association between recent exposure to CGM-recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes. Accepted Diab Obes Metab April 2024 

Kadiyala N, Wilinska ME, Daly AB, Nwokolo M, Lakshman R, Hartnell S, Ware J, Allen JM, Cezar A, Evans ML, Hovorka R​​, Boughton CK. Hypoglycemia and hyperglycemia according to type of diabetes and time of day: observations during fully closed-loop insulin delivery in adults with type 1 and type 2 diabetes. Accepted J Diab Sci Technol March 2024 PMID: 38613227 DOI 10.1177/19322968241242803 Online ahead of print. 

Martine-Edith G, Zaremba N, Divilly P, Søholm U, Broadley M, Baumann PM, Mahmoudi Z, Gomes M,  Ali N, Abbink EJ, Galan BE, Brøsen J, Pedersen-Bjergaard U, Vaag AA, McCrimmon RJ, Renard E, Heller S, Evans M, Cigler M, Mader JK, Amiel SA, Speight J, Pouwer F, Choudhary P for the Hypo-RESOLVE Consortium. Associations between hypoglycaemia awareness status and symptoms of hypoglycaemia among adults with type 1 and insulin-treated type 2 diabetes using the Hypo-METRICS app. Diab Technol Ther 2024 doi: 10.1089/dia.2023.0596 Online ahead of print. 

Marcovecchio ML, Hendriks AEJ, Delfin C, Battelino T, Danne T, Evans ML, Johannesen J, Kaur S, Knip M, Overbergh L, Pociot F, Todd J, Van der Schueren B, Wicker LS, Peakman M, Mathieu C on behalf of the INNODIA consortium. The INNODIA Type 1 Diabetes Natural History Study – a European cohort of newly diagnosed children, adolescents and adults. Diabetologia Online Mar 22 2024. doi: 10.1007/s00125-024-06124-5 Online ahead of print. PMID: 38517484 

Haliloglu B, Boughton CK, Lakshman R, Ware J, Nwokolo M, Thabit H, Mader JK, Bally L, Leelarathna L, Wilinska ME, Allen JM, Hartnell S, Evans ML, Hovorka R Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogues in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes. Diab Technol Ther 2024 Feb 27. doi: 10.1089/dia.2023.0509 Online ahead of print. PMID: 38315506 

Martine-Edith G, Divilly P, Zaremba N, Søholm U, Broadley M, Baumann PM, Mahmoudi Z, Gomes M,  Ali N, Abbink EJ, Galan BE, Brøsen J, Pedersen-Bjergaard U, Vaag AA, McCrimmon RJ, Renard E, Heller S, Evans M, Cigler M, Mader JK, Speight J, Pouwer F, Amiel SA, Choudhary P for the Hypo-RESOLVE Consortium A comparison of the rates of clock-based nocturnal hypoglycemia and hypoglycemia whilst asleep among people living with diabetes: findings from the Hypo-METRICS study. Diab Technol Ther 2024 Apr 17. doi: 10.1089/dia.2023.0522 Online ahead of print. PMID: 38386436 

Fabricius TW; Verhulst CEM; Kristensen PL; Holst JJ; Tack CJ; McCrimmon RJ; Heller SR; Evans ML; de Galan BE; Pedersen-Bjergaard U. Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes – the Hypo-RESOLVE hypoglycaemic clamp study. Acta Diabetologica 2024 May;61(5):623-633. doi: 10.1007/s00592-024-02239-8. Epub 2024 Feb 20 PMID: 38376580 

Thabit H, Boughton C, Mubita W, Rubio J, Allen S, Heugh R, Mader JK, Narendran P, Evans M, Leelarathna L, Wilinska ME, Fullwood C, Garratt C, Hovorka R, Rutter MK. Impact of hybrid closed-loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data. Diabetes Obes Metab. 2024 Mar;26(3):1105-1109. doi: 10.1111/dom.15366. Epub 2023 Nov 20. PMID: 37984425; PMCID: PMC10872628.  

Lakshman R, Hartnell S, Ware J, Allen JM, Wilinska ME, Nwokolo M, Evans ML, Hovorka R, Boughton CK. Lived Experience of Fully Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024 Apr;26(4):211-221. doi: 10.1089/dia.2023.0394. Epub 2024 Feb 28. PMID: 38426909; PMCID: PMC10979660. 

Leelarathna L, Sutton CJ, Evans ML, Neupane S, Rayman G,  Lumley S, Cranston I,  Narendran P, Krishan A, Taxiarchi VP, Barnard-Kelly K, Elliott RA, Burns M, Camm M, Thabit H, Wilmot EG on behalf of the FLASH-UK Trial Study Group. Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study. Accepted Diabet Med Oct 2023 

Nwokolo M, Lakshman R, Boughton CK, Hartnell S, Alwan H, Ware J, Allen JM, Wilinska ME, Evans ML, Hovorka R. CamAPS FX hybrid closed-loop with ultra-rapid lispro compared with standard lispro in adults with type 1 diabetes: a double-blind, randomized, crossover study. Accepted Diabetes Technol Ther Sep 2023  

Elliott RA, Rogers G, Evans ML, Neupane S, Rayman G, Lumley S, Cranston I, Narendran P, Sutton CJ, Taxiarchi VP, Burns M, Thabit H, Wilmot EG, Leelarathna L on behalf of the FLASH–UK Trial Study Group. Estimating the cost effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabet Med. 2023 Sep 26:e15232. doi: 10.1111/dme.15232. Epub ahead of print. PMID: 37750427. 

Castillo-Armengol J, Sanchez-Archidona AR, Fledelius C, Evans M, McNeilly A, McCrimmon R, Marzetta F, Ibberson M, Thorens B. Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia. Diabetologia 67, 371–391 (2024). https://doi.org/10.1007/s00125-023-06043-x. PMID: 38206364 

Søholm U, Zaremba N, Broadley N, Axelsen JL, Divilly P, Martine-Edith G, Amiel SA, Mader JK, Pedersen-Bjergaard U, McCrimmon RJ, Renard E, Evans M, de Galan B, Heller S, Hendrieckx C, Choudhary P, Speight J, Pouwer F for the Hypo-RESOLVE Consortium. The Hypo-METRICS App: a mixed-methods investigation of content validity, acceptability, and feasibility in a 10-week study. Accepted JMIR Diabetes Aug 2023 

Boughton CK, Hartnell S, Lakshman R, Nwokolo M, Wilinska ME, Fuchs J, Allen JM, Evans ML and Hovorka R. Fully closed-loop glucose control with ultra-rapid insulin Lispro compared to insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and sub-optimal glycemic control: a single-centre, randomised, crossover study. Diabetes Care 2023 Aug 24:dc230728. doi: 10.2337/dc23-0728. Epub ahead of print. PMID: 37616583 

Edd SN, Castaneda J, Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Re R, Cellot J, de Portu S, Vorrink L, Shin J, van den Heuvel T, Cohen O, on behalf of the ADAPT study group. Twelve-month results of the ADAPT randomized controlled trial: reproducibility and sustainability of advanced hybrid closed loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Accepted Diab Obes Metab July 2023 https://doi.org/10.1111/dom.15217 

Schneider-Utaka A, Hanes S, Boughton CK, Hartnell S, Thabit H, Mubita WM, Draxlbauer K, Poettler T, Hayes J, Wilinska ME, Mader JK, Narendran P, Leelarathna L, Evans ML, Hovorka R, Hood K. Patient Reported Outcomes for older adults on CamAPS FX closed loop system. Diabet Med. 2023 Sep;40(9):e15126. doi: 10.1111/dme.15126. Epub 2023 May 23. PMID: 37171467. 

Alwan H,  Ware J,  Boughton CK, Wilinska ME,  Allen JM,  Lakshman R,  Nwokolo M,  Hartnell S,  Bally L,  de Beaufort C,  Besser REJ,  Campbell FM,  Davis N, Denvir L,  Evans ML,  Fröhlich-Reiterer E, Ghatak A,  Hofer SA,  Kapellen TM,  Leelarathna L,  Mader JK,  Narendran P, Rami-Mehrar B,  Tauschmann M, Thabit H,  Thankamony A,  Hovorka R; on behalf of the AP@home, DAN05, DAN06 and KidsAP consortia. Time spent in hypoglycemia according to age and time-of-day: Observations during closed-loop insulin delivery. Accepted Diab Technol Ther April 2023 

Søholm U, Broadley M, Zaremba N, Divilly P, Nefs G, Carlton J, Mader JK, Baumann P, Gomes M, Martine-Edith G, Pollard DJ, Rath D, Heller S, Pedersen-Bjergaard U, McCrimmon RJ, Renard E, Evans M, de Galan B, Forkmann T, Amiel SA, Hendrieckx C, Speight J, Choudhary P, Pouwer F on behalf of the Hypo-RESOLVE consortium. Psychometric properties of an innovative smartphone application to investigate the daily impact of hypoglycemia in people with type 1 or type 2 diabetes: The Hypo-METRICS app. Accepted PLoS ONE March 2023 

McNeilly AD, Gallagher JR, Evans ML, de Galan BE, Pedersen-Bjergaard U, Thorens B, Dinkova-Kostova AT, Huang J-T, Ashford MLJ, McCrimmon RJ on behalf of the Hypo-RESOLVE Consortium. Chronic hyperglycaemia increases the vulnerability of the hippocampus to oxidative damage induced during post-hypoglycaemic hyperglycaemia in a mouse model of chemically-induced type 1 diabetes. Diabetologia. 2023; 66(7):1340-1352. doi: 10.1007/s00125-023-05907-6. PMID: 37015997 

Ware J, Wilinska ME, Ruan Y, Allen JM, Boughton CK, Hartnell S, Bally L, de Beaufort C, Besser REJ, Campbell FM, Draxlbauer K, Elleri D, Evans ML, Fröhlich-Reiterer E, Ghatak A, Hofer SE, Kapellen TM, Leelarathna L, Mader JK, Mubita WM, Narendran P, Poettler T, Rami-Merhar B, Tauschmann M, Randell T, Thabit H, Thankamony A, Trevelyan N, Hovorka, R. Safety of User-Initiated Intensification of Insulin Delivery Using Cambridge Hybrid Closed-Loop Algorithm. J Diab Sci Tech Dec 2022. https://doi.org/10.1177/19322968221141924  

Fattah M, Boughton CK, Ware J, Allen JM, Hartnell S, Willinska ME, Thankamony A, de Beaufort C, Campbell FM, Fröhlich-Reiterer E, Hofer SE, Kapellen TM, Rami-Merhar B, Ghatak A, Randell TL, Besser REJ, Elleri D, Trevelyan N, Denvir L, Davis N, Bally L, Thabit H, Leelarathna L, Evans ML, Mader JK, and Hovorka RH. Evaluating the impact of applying personal glucose targets in CamAPS FX closed-loop system for people with type 1 diabetes. J Diab Sci Tech Dec 2022. DOI:10.1177/19322968221145184  

Daly AB, Boughton CK, Nwokolo M, Hartnell S, Wilinska ME, Cezar A, Evans ML, Hovorka R. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med. 2023 Jan;29(1):203-208. doi: 10.1038/s41591-022-02144-z. Epub 2023 Jan 11. PMID: 36631592; PMCID: PMC9873557. 

Thabit H, Boughton C, Mubita W, Rubio J, Mader JK, Narendran P, Evans M, Leelarathna L, Wilinska ME, Fullwood C, Gregory AM, Hovorka R, Rutter MK. Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes. Accepted Diab Obes Metab Nov 2022 

Zhang J-Y, Hamey F, Trzupek D, Mickunas M, Lee M, Godfrey L, Yang JHM,  Pekalski ML, Kennet J, Waldron-Lynch F, Evans ML, Tree TIM, Wicker LS, Todd JA and Ferreira RC. Low-dose IL-2 reduces IL-21+ T cells and induces anti-inflammatory gene expression in type 1 diabetes. Nature Communication 13, 7324 (2022). https://doi.org/10.1038/s41467-022-34162-3 

Also available as pre-print:  

Jia-Yuan Zhang, Fiona Hamey, Dominik Trzupek, Marius Mickunas, Mercede Lee, Leila Godfrey, Jennie H.M. Yang, Marcin L Pekalski, Jane Kennet, Frank Waldron-Lynch, Mark Evans, Timothy I. M. Tree, Linda S. Wicker, John A. Todd and Ricardo C. Ferreira. Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients. Deposited medRxiv April 5th 2022: doi: https://doi.org/10.1101/2022.04.05.22273167 

Leelarathna L, Evans ML, Neupane S,  Rayman G,  Lumley S, Cranston I,  Narendran P, Barnard-Kelly K, Sutton CJ, Elliott RA, Taxiarchi VP, Gkountouras G, Burns M, Mubita  W, Kanumilli N, Camm M, Thabit H,  Wilmot EG on behalf of the FLASH-UK Trial Study Group. Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes. New Engl Journal of Med 2022 Oct 20;387(16):1477-1487. doi: 10.1056/NEJMoa2205650. Epub 2022 Oct 5. 

Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, de Portu S, Vorrink L, Shin J, Habteab A, Castañeda J, da Silva J, Cohen O on behalf of the ADAPT study Group. Advanced Hybrid Closed Loop study in An Adult Population with Type 1 Diabetes (ADAPT): A Randomized Controlled Study. Lancet Diabetes & Endocrinology 2022 Oct;10(10):720-731. PMID: 36058207 DOI: 10.1016/S2213-8587(22)00212-1